References

1. Faderl S, Talpaz M, Estrov Z, Kantarjian HM: Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131:207-219, 1999.

2. Kantarjian HM, Smith T, O'Brien S, et al.: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-therapy. Ann Intern Med 122: 254-261, 1995.

3. O'Brien S, Kantarjian H, Koller C, et al.: Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93:4149-4153, 1999.

4. O'Brien S, Talpaz M, Cortes J, et al.: Simultaneous homo-harringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94:2024-2032, 2002.

5. Baccarani M, Rosti G, de Vivo A, et al.: A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99:1527-1535, 2002.

6. Kantarjian HM, O'Brien S, Smith TL, et al.: Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 17: 284-292, 1999.

7. Guilhot F, Chastang C, Michallet M, et al.: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group [see comments]. N Engl J Med 337:223-229, 1997.

8. Kantarjian HM, O'Brien S, Cortes JE, et al.: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033-1041, 2003.

9. Hochhaus A, Reiter A, Saussele S, et al.: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95:62-66, 2000.

10. Molldrem JJ, Lee PP, Wang C, et al.: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018-1023, 2000.

11. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review, 1975-2001, Vol. 2004. Bethesda, MD: National Cancer Institute; 2004. Available at: http://seer.cancer.gov/csr/1975a2001/

strategy for young patients with the option of an allogeneic stem cell transplant, and probably either option is appropriate as a first-line therapy. Adequate management is particularly important in these patients if one is to optimize the probability of achieving long-term durable remissions and minimize the risks for the majority of patients with CML.

12. Radich JP, Gooley T, Bensinger W, et al.: HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31-35, 2003.

13. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA: Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 20:2334-2343, 2002.

14. Weisdorf DJ, Anasetti C, Antin JH, et al.: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:19711977, 2002.

15. Or R, Shapira MY, Resnick I, et al.: Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441-445, 2003.

16. Clift RA, Buckner CD, Thomas ED, et al.: Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 84:4368-4373, 1994.

17. Gratwohl A, Hermans J, Niederwieser D, et al.: Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 12:509-516, 1993.

18. Morton AJ, Gooley T, Hansen JA, et al.: Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394-401, 1998.

19. Giralt SA, Kantarjian HM, Talpaz M, et al.: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055-1061, 1993.

20. Giralt S, Szydlo R, Goldman JM, et al.: Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood 95:410-415, 2000.

21. Hehlmann R, Hochhaus A, Kolb HJ, et al.: Interferonalpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94:3668-3677, 1999.

22. Lee SJ, Klein JP, Anasetti C, et al.: The effect of pretrans-plant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 98:3205-3211, 2001.

23. Holowiecki J, Kruzel T, Wojnar J, et al.: Allogeneic stem cell transplantation from unrelated and related donors is effective in CML Ph+ and ALL Ph+ patients pretreated with imatinib [abstract]. Blood 102:436b, 2003. Abstract #5473.

24. Prejzner W, Zaucha JM, Szatkowski D, et al.: Imatinib therapy prior to myeloablative allogeneic stem cell transplantation does not increase acute transplant related toxicity [abstract]. Blood 102:911a, 2003. Abstract #3389.

25. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001.

26. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002.

27. Kantarjian HM, Cortes JE, O'Brien S, et al.: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferonalpha. Blood 104:1979-1988, 2004.

28. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

N Engl J Med 348:994-1004, 2003.

29. Hahn EA, Glendenning GA, Sorensen MV, et al.: Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138-2146, 2003.

30. Kantarjian H, O'Brien S, Cortes J, et al.: Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferonalpha regimens for early chronic phase. Cancer 98:14301437, 2003.

31. Kantarjian HM, Cortes JE, O'Brien S, et al.: Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloge-nous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101:97-100, 2003.

32. Cortes J, Giles F, O'Brien S, et al.: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102:83-86, 2003.

33. Hughes T, Branford S, Matthews J, et al.: Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase [abstract]. Blood 102:31a, 2003. Abstract #95.

34. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114:532-538, 1991.

35. Radich JP, Gehly G, Gooley T, et al.: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85:2632-2638, 1995.

36. Radich JP, Gooley T, Bryant E, et al.: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 98:1701-1707, 2001.

37. Hughes TP, Kaeda J, Branford S, et al.: Molecular responses to Imatinib (STI571) or Interferon + Ara-C as initial therapy for CML; results of the IRIS Study [abstract]. Blood 100:93a, 2002. Abstract #345.

38. Cortes J, O'Brien S, Talpaz M, et al.: Clinical significance of molecular response in chronic myeloid leukemia after imatinib (Gleevec) therapy: low levels of residual disease predict for response duration [abstract]. Blood 102:416a, 2003. Abstract #1513.

39. Rosti G, Martinelli G, Bassi S, et al.: Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 103:2284-2290, 2004.

40. O'Dwyer ME, Mauro MJ, Blasdel C, et al.: Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103:451-455, 2004.

41. Cortes JE, Talpaz M, Giles F, et al.: Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101:3794-3800, 2003.

42. Cortes J, O'Dwyer ME: Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18:671-684, 2004.

43. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98:1905-1911, 2003.

44. Bumm T, Muller C, Al-Ali HK, et al.: Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941-1949, 2003.

45. Kantarjian H, Talpaz M, O'Brien S, et al.: Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97:2225-2228, 2003.

46. Druker BJ, Gathmann I, Bolton AE, Larson RA, IRIS: Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase [abstract]. Blood 102:182a, 2003. Abstract #634.

47. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204-2205, 2004.

48. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28:71-73, 2004.

49. Ghanima W, Kahrs J, Dahl TG, III, Tjonnfjord GE: Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 72:441-443, 2004.

50. Graham SM, Jorgensen HG, Allan E, et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325, 2002.

51. Sneed TB, Kantarjian HM, Talpaz M, et al.: The significance of myelosuppression during therapy with ima-tinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100:116-121, 2004.

52. Kantarjian H, Talpaz M, O'Brien S, et al.: High-dose ima-tinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004.

53. Cashen A, DiPersio JF, Khoury H: Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia? J Clin Oncol 21:4255-4256, 2003.

54. Deininger MW, O'Brien SG, Ford JM, Druker BJ: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21:1637-1647, 2003.

55. Quintas-Cardama A, Kantarjian H, O'Brien S, et al.: Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100:2592-2597, 2004.

56. Mauro MJ, Kurilik G, Balleisen S, O'Dwyer ME, Reese SF, Druker B: Myeloid growth factors for neutropenia during iamtinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Blood 98:139a, 2001.

57. Marin D, Marktel S, Foot N, et al.: G-CSF reverses cytopenia and may increase cytogenetic responses in patients with CML treated with imatinib mesylate [abstract]. Blood 100:782a, 2002. Abstract #3091.

58. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J: Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res 28:613-618, 2004.

59. Cortes J, O'Brien S, Quintas A, et al.: Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100:2396-2402, 2004.

60. Mauro MJ, Blasdel C, O'Dwyer ME, Kurilik G, Capdeville R, Druker B: Erythropoietin for anemia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy [abstract]. Proc ASCO 21:27a, 2002. Abstract #106.

61. Ault P, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Cortes J: Use of darbopoietin alfa for the treatment of anemia occuring during imatinib therapy for CML: preliminary evidence of safety and efficacy [abstract]. Proc ASCO 22:613, 2003. Abstract #2467.

62. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R: Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myel-ogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94:1383-1389, 1994.

63. Branford S, Rudzki Z, Parkinson I, et al.: Real-time quantitative PCR analysis can be used as a primary screen to identify imatinib-treated patients with CML who have BCR-ABL kinase domain mutations. Blood 104:2926-2932, 2004.

This page intentionally left blank

Chapter 19

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment